(Q34239882)

31 July 2017

1 reference

title

Medical management of mild-to-moderate heart failure before the advent of beta blockers (English)

1 reference

31 July 2017

1 reference

Abraham WT

1

1 reference

31 July 2017

Wagoner LE

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 7A

1 reference

31 July 2017

page(s)

47S-62S

1 reference

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

The treatment of heart failure: The Task Force of the Working Group on Heart Failure of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Results of coronary artery surgery in patients with poor left ventricular function (CASS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Reversal of chronic ischemic myocardial dysfunction after transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Resolution of congestive failure, mitral regurgitation, and angina after percutaneous transluminal coronary angioplasty of triple vessel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

The natural course of alcoholic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Importance of abstention from alcohol in alcoholic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effects of acetylsalicylic acid on renal function in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Acute Oliguric Renal Failure Induced by Indomethacin: Possible Mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effects of physical training in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Cardiac rehabilitation for heart failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Arm exercise training in the rehabilitation of patients with impaired ventricular function and heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

A Study by Continuous Microperfusion of Water and Electrolyte Movements in the Loop of Henle and Distal Tubule of the Rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of diuresis on the performance of the failing left ventricle in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium Retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

The physiologic basis of diuretic synergism: its role in treating diuretic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Cross-over comparison of the fixed combination of hydrochlorothiazide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Comparison of lisinopril versus placebo for congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Controlled trial of enalapril in congestive cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Hemodynamic effects of captopril in patients with severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Long-term digitalis therapy improves left ventricular function in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Heart failure in outpatients: a randomized trial of digoxin versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Convert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Sudden death in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Ventricular arrhythmias in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Ventricular arrhythmias in dilated cardiomyopathy: Efficacy of amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Intracardiac thrombi and systemic embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

Sudden death in patients with congestive heart failure: future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900386-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00386-6

1 reference

31 July 2017

1 reference